Evidence map›Paper›PMID 12793967›Full record

ReviewCurrent atherosclerosis reports2003

Antithrombotic and thrombolytic therapy for ischemic stroke.

Curtis Benesch

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current atherosclerosis reports, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 94% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Curtis BeneschDepartment of Neurology, University of Rochester School of Medicine and Dentistry, Box 681, 601 Elmwood Avenue, Rochester, NY 14642, USA. curtis_benesch@urmc.rochester.edu
University of Rochester · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antithrombotic therapy is the mainstay of treatment for stroke prevention. Multiple antiplatelet agents are now proven options for patients at risk for stroke, whereas warfarin anticoagulation remains the preferred therapy for most patients with atrial fibrillation. Recent clinical trials have clarified the role of anticoagulation in acute stroke and in secondary prevention of noncardioembolic stroke. Intravenous tissue plasminogen activator is the only approved therapy for patients with acute ischemic stroke. Intra-arterial thrombolysis is emerging as a promising therapy in selected patients.

Indexed as

AnticoagulantsBrain IschemiaHumansPlatelet Aggregation InhibitorsStrokeThrombolytic TherapyWarfarinAnticoagulantsPlatelet Aggregation InhibitorsWarfarin

Identifiers

PMID12793967
OpenAlexW1964337132

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.